Navigation Links
Volcano Corporation Announces Pricing of Common Stock Offering
Date:10/17/2007

SAN DIEGO, Oct. 18 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC) announced today the pricing of its public offering of 7,000,000 shares of its common stock at a price of $16.25 per share. All of the shares are being offered by Volcano. Volcano has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock to cover over-allotments, if any. The offering is expected to close on October 23, 2007, subject to the satisfaction of customary closing conditions.

J.P. Morgan Securities Inc., Banc of America Securities LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with Bear, Stearns & Co. Inc. acting as co-manager. Information about the offering is available in the prospectus supplement and accompanying prospectus for the offering filed with the Securities and Exchange Commission.

Copies of the prospectus supplement and accompanying prospectus can be obtained by contacting J.P. Morgan Securities Inc., Prospectus Library, Four Chase Metrotech Center, CS Level, Brooklyn, NY 11245; Banc of America Securities LLC, Capital Markets (Prospectus Fulfillment) by e-mail to dg.prospectus_distribution@bofasecurities.com or by mail to Banc of America Securities LLC, Capital Markets Operations, 100 West 33rd Street, Third Floor, New York, N.Y. 10001; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402.

A shelf registration statement relating to the securities being offered has been filed with the Securities and Exchange Commission and has become effective. This news release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures and enhance the diagnosis of and guide therapies for vascular and structural heart diseases.

This press release contains "forward-looking" statements, including statements related to Volcano's plans to complete a public offering. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Volcano's results to differ materially from those indicated by these forward-looking statements, including risks and uncertainties related to satisfaction of the public offering's customary closing conditions, as well as other risks detailed from time to time in Volcano's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2006. Volcano does not undertake any obligation to update forward-looking statements.


'/>"/>
SOURCE Volcano Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being enlisted ... bacteria that live in and on the human body –and are believed ... The Microbiome Immunity ... human microbiome, starting with the gut. The project's goal is to help ... credit: IBM ...
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):